A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which led to serious complications such as kidney failure--the FDA has asked Lilly and its partner on the drug, Amylin [1], to revise its labeling.

With $430.2 million in 2006 sales, Byetta delivered some $219 million in revenues to Lilly. The rest went to Amylin, accounting for 90 percent of that company's sales. Amylin stock fell sharply on the news.

- check out the report [2] from the Indianapolis Star

Related Articles:
In speech, Lilly CEO calls for drug monitoring. Report [3]
Lilly developing biotech drugs the old-fashioned way. Report [4]
Amylin shares shoot up on Phase II Byetta results. Report [5]
Diabetes epidemic triggers soaring drug market. Report [6]

Read more on: Eli Lilly [7] | Diabetes [8] | Amylin [9]